StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

Research analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Several other research firms also recently commented on CTSO. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research note on Monday, January 13th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Down 1.9 %

Shares of NASDAQ CTSO opened at $1.02 on Tuesday. The stock has a market cap of $55.77 million, a PE ratio of -2.83 and a beta of 0.58. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.59. The business has a 50-day moving average price of $0.94 and a 200 day moving average price of $1.04. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Thursday, November 7th. The medical research company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The business had revenue of $9.39 million during the quarter, compared to analyst estimates of $10.14 million. During the same period in the previous year, the firm earned ($0.21) earnings per share. Equities research analysts forecast that Cytosorbents will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares in the last quarter. Sargent Investment Group LLC raised its holdings in shares of Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after acquiring an additional 192,747 shares during the last quarter. Finally, Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents in the third quarter valued at $51,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.